ArticleBMC infectious diseases2025
Prevalence of post-pandemic SARS-CoV-2 in patients with respiratory syndrome in Brazzaville, Republic of the Congo.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Speeding up respiratory diagnosis: clinical drivers, barriers, and system readiness for rapid molecular point-of-care testing in Saudi Arabia.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The first confirmed case of COVID-19 was detected in the Republic of the Congo in March 2020. Several control measures were implemented during the pandemic period. As a result, the number of reported cases decreased significantly, leading to the gradual lifting of barrier measures and the declaration of the end of the outbreak on 14 October 2022. The present study aimed to determine the post-pandemic prevalence of SARS-CoV-2 in the referral hospitals of Talangaï (HRT) and Makélékélé (HRM) in Brazzaville between October 2022 and April 2023. Nasopharyngeal samples collected from patients with respiratory syndrome were analyzed via qRT‒PCR to detect SARS-CoV-2. An overall prevalence of 5% of SARS-CoV-2 infection was found, with monthly fluctuations in cases during the study period, likely reflecting the endemic nature of the infection. The monthly proportion of SARS-CoV-2 infection cases did not correlate with the number of patients with respiratory syndrome-related symptoms. Although the post-pandemic prevalence of SARS-CoV-2 has remained low, laboratory confirmation of COVID-19, which accounts for both clinical suspicion and detection of SARS-CoV-2, using at least one rapid diagnostic test (RDT) is needed to improve case-by-case management in health centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.